Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (MV-deltaC virus) in cancer therapy
AssigneesCentre National De La Recherche Scentifique (Cnrs), Insitut National de la Sante et de la Recherche Medicale (INSERM), Institut Pasteur, Universite De Nantes
InventorsFrédéric Tangy, Marc Gregoire, Jean-François Fonteneau, Jean-Baptiste Guillerme, Chantal Combredet
Life of this patent
Estimating the term…
Abstract
The invention relates to a genetically modified infectious measles virus derived from a live-attenuated measles virus strain, in which the gene encoding the viral accessory C protein has been knocked out (MV-deltaC). It concerns in particular the use of said genetically modified infectious MV-deltaC in the treatment of malignant tumor or cancer conditions, and for the preparation of agents or compositions for such treatment.
Claims6
A method of treating melanoma in a subject in need thereof, comprising administering an effective amount of an infectious live-attenuated measles virus (MV) strain to the subject, wherein the gene encoding the viral accessory C protein has been knocked out in the infectious live-attenuated MV (MV-deltaC).
Dependencies are inferred from the claim text.